In this multicenter retrospective study, the outcomes of 836 patients with myelodysplastic syndrome (MDS) who underwent transplantation with an HLA-identical sibling donor were analyzed according to two types of conditioning: reduced-intensity conditioning (RIC) in 215 patients, and standard myeloablative (or high dose) conditioning (SMC) in 621 patients.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potential curative treatment option for patients with myeloid malignancies, including high-risk myelodysplastic syndromes (MDS) and secondary acute myelogenous leukemia (sAML).
Standard myeloablative conditioning (SMC) regimens for patients with myeloid malignancies usually consists of the combination of cyclophosphamide and high-dose total body irradiation (TBI) or high-dose busulphan [1] [2] [3] [4] [5] [6] [7] [8] [9] . A serious limitation of these regimens is the associated toxicity that requires intense supportive care and predisposes debilitated and elderly patients to a high risk of non-relapse mortality (NRM) from direct organ toxicity, infections and graft-versus-host disease (GVHD) [10] [11] [12] . Recipient age, disease-related risk factors and the intensity of the conditioning regimen, among other variables, are important predictors of post-HSCT outcome 12 . Specifically, the high NRM in elderly and debilitated patients precludes the use of SMC regimens in many patients with high-risk MDS or sAML.
Less toxic conditioning regimens, collectively referred to as reduced-intensity conditioning (RIC) regimens, have been developed by using lower doses of alkylating agents or TBI, usually in combination with fludarabine [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . A large number of RIC regimens have been described in small and heterogeneous groups of patients with MDS, and thus currently the "optimal" RIC regimen is unknown. Current data suggests that RIC regimens do reduce the early morbidity and NRM in high-risk patients, while allowing sustained engraftment of allogeneic hematopoietic stem cells not only from matched related but also from unrelated donors [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . On the other hand, the incidence of disease relapse in MDS and AML may increase if the dose-intensity of the conditioning is reduced 17, 18, 27, 28 . It is obvious that the final result of these opposite effects of RIC regimens on the outcome of HSCT for MDS is extremely relevant.
In this retrospective, multicenter study, we evaluated the role RICs and SMC regimens in the outcome of patients receiving HLA-identical sibling HSCT for MDS and sAML.
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Patients and Methods

Patient and transplantation characteristics and definitions
Patient details are shown in table 1. Included in the study were 993 patients, from 128 centers, with a primary diagnosis of MDS (refractory anemia (RA), RA with ring sideroblasts (RARS), RA with excess of blasts (RAEB), RAEB in transformation (RAEB-t), 2 ), IV cyclophosphamide (600 to 120 mg/m 2 ) or IV thiotepa (5-10 mg/kg). In 157 patients, the exact doses of cytotoxic drugs and/or TBI were not available, and we defined them as "unknown" type conditioning regimen, and their impact on outcomes was analyzed as detailed in the section on statistical methods. Unless otherwise specified, results refer to the 836 patients with a well-classified type of conditioning regimen. Informed consent was obtained locally in accordance with the principles laid out in the Declaration of Helsinki and according to the local and national approvals applicable according to the specific trial followed by each center.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From For GVHD prophylaxis, in vitro T cell depletion was more common in the SMC group (22% in the SMC vs. 5 % in the RIC regimens, P<0.01). Among non-T-cell depleted transplants, the combination of cyclosporine A (CsA) plus methotrexate (MTX) was more common in the SMC, while CsA alone was more common in the RIC group (table 2) . The use and dosage of alemtuzumab or ATG was reported in only 5% and 23% of the study cohorts, respectively. This variable was not uniformly entered into the EBMT database in most patients, and thus the impact on transplant outcomes of these commonly used antibodies in many RIC regimens published cannot be performed in the current study.
As expected, baseline patient characteristics differed between both study groups. For instance, median recipient age at transplantation was 45 years for the SMC and 56 years for the RIC group (P < 0.0001). Other relevant differences are shown in table 1. We were able to collect sufficient data on cytogenetics or cytopenias in order to calculate the international prognostic scoring system (IPSS) for MDS in about 50% of patients in both transplant groups 31 (as shown in table 1). Disease morphology was classified according to the FrenchAmerican-British (FAB) classification, and the worst FAB type pre-HSCT was considered for the analyses. For classifying the disease status at transplant, we took into account if complete remission (CR) was achieved with AML-type chemotherapy prior to the transplant conditioning or if the patient did not receive such treatment or was refractory to chemotherapy or no longer in CR. Three hundred and twenty-four patients did not receive AML-type (i.e., remission-induction) chemotherapy before HSCT, and they accounted for the "untreated group", which represented similar proportions of patients in both study groups (38% in the SMC vs. 42 % in the RIC regimens). Additionally, the proportion of patients in first CR after chemotherapy was similar (34% vs. 31 %, respectively). The remaining 235
patients accounted for the "treated, not in first CR" group because they were in second or later CR or were either refractory, in partial response or with progressive disease after chemotherapy (28% vs. 27%, respectively). Detailed results of cytogenetic data were available in 311 (37%) patients (40% in the SMC vs. 29 % in the RIC regimens, P=0.008). Disease phase at transplant (not disease status, as described above) was defined as early phase (<5% marrow blasts: untreated RA/RARS or RAEB, RAEB-t and sAML in first CR with intensive chemotherapy), or non-early phase (>5% marrow blasts). The source of stem cells was PBSC in 51% in the SMC vs. 87% in the RIC regimens (P<0.0001). Due to the retrospective nature of the study, the reason(s) for inclusion in a RIC protocol and exclusion from a SMC in each transplant group were not known. In the EBMT database, acute and chronic GVHD (aGVHD and cGVHD) are graded using established criteria 30 .
End point definitions
End points were assessed on the date of last patient contact, and the final database was updated on December 2005. Median follow-up time from transplantation for the patients alive at last update was longer in the SMC group (50 months vs. 38 months in the RIC regimens, P<0.05). Analysis focused on hematopoietic recovery, aGVHD and cGVHD, NRM, disease relapse (REL) or progression, progression-free survival (PFS), and overall survival (OS). The date of neutrophil recovery was defined as the first of 3 consecutive days with an absolute neutrophil count above 0.5 × 10 9 /L, while the date of platelet recovery was defined as the first of 7 consecutive days with a platelet count higher than 50 × 10 9 /L.
Analysis of cGVHD included patients who had neutrophil recovery and survived without disease progression for more than 90 days from transplantation; cases were coded as absent, limited, or extensive. Transplant outcomes were analyzed at 3 years after transplant, although outcomes at earlier time points are shown in table 3.
Statistical methods
The probabilities of PFS and OS were estimated from the time of transplantation, using Kaplan-Meier curves. Groups were compared using the 2-tailed log-rank test. The hematopoietic recovery and occurrence of GVHD, NRM, and disease relapse or progression were calculated using cumulative incidence estimates, taking into account the competing risk structure 31, 32 . Univariate analyses of these latter outcomes were performed using univariate Cox regression models. In addition to the type of conditioning regimen used before HSCT (main study variable), the following covariates were analyzed in univariate analysis: recipient age at transplantation (continuous covariate; 50 years and younger vs.
older than 50 years for display purposes), year of transplantation (1998-2000 vs. 2001-2002 of conditioning regimen and the other remaining covariates were tested adding cross-product terms to the model in a forward stepwise way. Grade II-IV aGVHD was introduced in the final models for NRM, relapse, PFS and OS as a time-dependent covariate. Departure from the proportional hazards assumption was assessed using methods based on partial residuals and a graphical approach. If the proportional hazards assumption did not hold for a covariate, stratified or extended Cox models with time-dependent covariates were considered to assess whether the estimate of the main risk factor (conditioning regimen) would be biased due to a model mis-specification. If this was not the case, we accepted a small deviation from the proportional hazards assumption in secondary covariates.
When groups were compared according to continuous covariates, the Mann-Whitney U test or. Kruskal-Wallis one-way analysis of variance on ranks test were used for differences in medians. According to the group sizes, a chi-square analysis or Fisher's exact test was used to compare categorical covariates. SPSS version 11 was used for all statistical analyses. All the above analyses were first executed in the entire patient cohort (n=993, including the 157 patients with an undefined type ("missing") of conditioning regimen), and then in the 836 patients with a clearly defined type of conditioning regimen (because the other covariate patterns might be influenced by the group of 157 patients and hence correction for confounding might be different). In both approaches the condition regimen was used as a factor, in the first with 3 levels, in the 2nd analysis with only 2 levels. This separate analysis was intended to identify whether the "missing" group of patients had any different outcomes that would suggest a selection bias. Since the results from this group did not differ from the other 836 patients, and did not influence the final multivariate models, the analyses will refer to the comparison of SMC and RIC conditioning regimens, unless specified otherwise 
Results
Hematopoietic recovery
Neutrophil recovery occurred in all but 37 patients (4% in the SMC group and 6% in the RIC group; P = 0.3), with a median time to reach an absolute neutrophil count above 0.5 × 10 9 /L of 16 days in the SMC group and 14 days in the RIC group (P = 0.001). Median time to achieve a platelet count above 50 × 10 9 /L was 23 and 16 days, respectively (P < 0.0001). The reported frequency of graft failure (primary plus secondary) was similar between groups, as shown in table 3.
GVHD
AGVHD developed in 362/621 (58%) patients in the SMC group and 92/215 (43%) in the RIC group, resulting in a 100-day cumulative incidence of 65% and 46, respectively (P<0.001). The number of each grade of aGVHD is shown in table 3. The median day of onset of aGVHD was +15, without differences between groups. CGVHD developed within one year post-transplant in 210/400 (52%) evaluable patients in the SMC group (109 limited and 101 extensive cGVHD) and 59/132 RIC (45%) patients (31 limited and 28 extensive forms).
Non-relapse mortality (NRM)
The 3-month and 3-year incidences of NRM were 20% and 32% in the SMC, and 15% and 22% in the RIC group, respectively [P=0.04] (table 3 and figure 1 ). In univariate analysis, the variables that were associated with an increased 3-year NRM were:
(1) use of SMC regimens (P=0.03); (2) patient age >50 years (P=0.004); (3) For personal use only. on October 24, 2017. by guest www.bloodjournal.org From incidence of NRM in patients > 50 years old was 57% in the SMC vs. 32% in the RIC group (P=0.01). Additionally, the 3-year NRM was higher with SMC in all disease statuses at transplant, as shown in detail in figure 3 .
Disease relapse or progression (REL)
One hundred and sixty-one (26%) in the SMC and 87 (40%) in the RIC group progressed or relapsed, resulting in a 3-year cumulative incidence of 27% and 45%, respectively (P<0.01 in univariate analysis), as shown in table 3 and figure 1. In univariate analysis, the variables that were associated with an increased 3-year incidence of REL were:
(1) use of RIC regimens (P<0.01); (2) disease status not in first CR after chemotherapy at transplant (P<0.001); (3) pharmacological GVHD prophylaxis with ATG or alemtuzumab vs. other(s) (P<0.05); (4) advanced disease phase at transplant (P<0.05); (5) poor-risk karyotype (P<0.001); and (6) time interval from diagnosis to transplant other than 3 to 6 months (P=0.03). Table 5 shows in detail results of the multivariate analysis, which identified 4 variables to be associated with increased 3-year REL risk, including the use of RIC regimens (P=0.001). The cumulative incidences of REL in patients aged less than or more than 50 years old were higher in the RIC group (age > 50 years, 38% in the SMC vs. 59% in the RIC group; and in < 50 years old, 28% vs. 51%, respectively). As shown in figure 2, the 3-year incidence of transplant failure (NRM + REL) were nearly identical with both types of conditioning regimens in all age categories, since a lower NRM in the RIC group was counterbalanced by higher REL. Additionally, the REL was lower with SMC in all disease statuses at transplant, as shown in detail in figure 3 . The largest difference is in the chemorefractory group (treated with AML-type but not achieved first CR at transplant), with a 3-year REL incidence of 37% vs. 65%, respectively.
Survival
As shown in table 3, the type of transplant conditioning had no impact on the 3-year probabilities of OS and PFS; the 3-year OS was 45% in the SMC group and 41% in the RIC group (P=0.7), while PFS was 41% and 33%, respectively (P=0.4).
PFS.
In univariate analysis, the variables that decreased the 3-year PFS probability were: (1) sAML vs. other MDS types (P=0.03); (2) disease status not being in first CR at transplant (P<0.001); (3) age > 50 years (P=0.05); (4) poor-risk karyotype (P=0.03); (5) time interval from diagnosis to transplant other than 3 to 6 months (P=0.03); (6) BM as stem cell source (P=0.04); and (7) donor or recipient seropositive for CMV pre-transplant (P=0.06). Table 6 shows in detail results of the multivariate analysis, in which 3 variables were found to decrease the 3-year probability of PFS: (1) sAML vs. other MDS types; (2), disease status not being in first CR at transplant; and (3) age > 50 years, while RIC showed no influence on PFS (P=0.9).
OS.
In univariate analysis, variables that decreased the 3-year OS were: (1) patient age > 50 years (P=0.009); (2) disease status not being in first CR at transplant (P<0.001); (3) sAML vs. other MDS types (P=0.03); (4) time interval from diagnosis to transplant other than 3 to 6 months (P=0.06); (5) low CD34+ cell dose infused (P=0.04); and (6) BM as stem cell source (P=0.06). In multivariate analysis, the variables that decreased OS are shown in table 7, and RIC had no impact on 3-yr. OS: (1) patient age > 50 years; (2) sAML vs. other MDS type; and (3) disease status not being in first CR at transplant (detailed in table 7). Figure 4 shows the adjusted probability of OS by transplant group and disease status. OS was similar in both transplant groups in all disease statuses (notably, treated but not in first CR (33% in SMC vs. 33% in RIC) and first CR (56% vs. 57%, respectively).
Discussion
The current study has confirmed the impact of previously observed risk factors on the outcome of HSCT from an HLA-identical sibling using SMC regimens, including age, disease phase and status at time of transplantation, type of MDS (RA and RARS with a better outcome), the cytogenetic risk category, and, more recently, the source of stem cells and number of CD34+ cells infused [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 33, 34 was the strongest negative predictor of NRM, with a corresponding impact on PFS and OS, but not on MDS relapse. The other most significant variable that had a prognostic impact on outcome in most studies is MDS "risk category". Risk category can be classified by the type of MDS (RA, RARS being low-risk and all other types, especially sAML, being high-risk), the percentage of BM blasts at HSCT, the cytogenetic risk group and/or the international prognostic scoring system (IPSS) 10, 35 In this regard, our results, which include a large number of patients transplanted in a recent period, identified similar prognostic factors. In addition, PBSC as stem cell source showed a trend toward reducing the NRM, confirming a prior study from the EBMT 6 . Unfortunately, we were unable to test the prognostic impact of the IPSS, since the variables required for calculating the IPSS score were not available for a relatively large proportion of patients, which was similar in both study groups (see table 1 ).
However, the IPSS had no impact in univariate analysis in the 55% of SMC and 57% RIC recipients for whom the IPSS could be estimated (data not shown n detail).
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The results from this large retrospective study show that RIC regimens may reduce the 3-year NRM after allogeneic HSCT for MDS when compared to SMC regimens, but with a higher risk of disease relapse and no impact on OS and PFS. The reduction of NRM in multivariate analyses is a promising finding, since patients who received a RIC are likely to have serious comorbidities, which led the transplant center to choose for a RIC, and surely many of these patients would not have received a HSCT with a SMC in most institutions.
In general the results of allogeneic HSCT have improved over time in all disease categories and donor types. In MDS, the EBMT analyzed the treatment outcome of patients transplanted in three consecutive time periods, showing a progressive improvement in the 3-year OS and PFS, mainly due to a decrease in NRM 5 . Thus, it is important that the current study includes SMC and RIC allografts during the same period (1997 to 2001) . Although all transplants were from an HLA-identical sibling, both transplant groups were heterogeneous regarding the exact types of conditioning regimens used, and, as previously emphasized, some important disease-related or conditioning-related variables were not available for most cases, especially patients' comorbidities 36 . These handicaps are common to most retrospective registry studies, and can only be partially corrected by the large number of patients analyzed. Other important deleterious variables for many outcomes were confirmed in the current study, mainly high-risk MDS and sAML (especially if not in first CR at transplant), older age, poor-risk cytogenetics, and low CD34+ cell numbers infused.
Nevertheless, only prospective randomized studies with analyses based on the intention-totreat principle may overcome the multiple possible selection biases inherent in retrospective registry analyses. In this respect, the EBMT MDS subcommittee of the CLWP has launched a prospective randomized study comparing SMC with a homogeneous fludarabine plus busulphan-based RIC.
In the current study transplants performed from 3 to 6 months after diagnosis showed a trend for a higher OS, and, in general, prior studies showed that longer duration of MDS For personal use only. on October 24, 2017. by guest www.bloodjournal.org From CMV, cytomegalovirus; M/F, male/female; FAB, French-American-British; AML, acute myelogenous leukemia; RA, refractory anemia; RAEB, RA with excess blasts; RAEB-t. RAEB in transformation; MDS, myelodysplastic syndromes; IPSS, international prognostic scoring system; CR, complete remission; BM, bone marrow; IPSS, international prognostic scoring system (reference 29). *CD34+ cell dose below and above the median for each stem cell source are classified as low and high cell dose infused, respectively **Refers to the comparison of cytogenetic risk group in the 311 patients with available data. # The IPSS risk group was not available in 257 (41%) and 92 (43%) patients in the standard myeloablative and reducedintensity conditioning groups, respectively
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Abbreviations: AML = acute myelogenous leukemia * Reference group Other variables with non-significant trend toward increasing relapse (P value, 0.06 to 0.1): (1) pharmacological GVHD prophylaxis with antithymocyte globulin or alemtuzumab (0.10); and (2) Interval from diagnosis to transplant other than 3 and 6 months (P=0.1). $ Some risk factors in the COX model contain a category for "unknown" to avoid loss of information; the overall p-value between brackets denotes the p-value of the complete risk factor; the individual p-values denote the p-values of the given contrasts to the reference category. For clarity sake the "unknown" categories as well as the non-significant risk factors have been omitted from the table ** A hazard ratio less tan 1.0 indicates that the variable leads to a reduction of disease relapse, while a value above 1.0 indicates that it leads to an increase in relapse Abbreviations: AML = acute myelogenous leukemia * Reference group Other variables with non-significant trend toward decreasing the PFS (P value, 0.06 to 0.1): (1) Interval from diagnosis to transplant other than 3 to 6 months (P=0.07); and (2) poor-risk cytogenetics (0.098). $ Some risk factors in the COX model contain a category for "unknown" to avoid loss of information; the overall p-value between brackets denotes the p-value of the complete risk factor; the individual p-values denote the p-values of the given contrasts to the reference category. For clarity sake the "unknown" categories as well as the non-significant risk factors have been omitted from the table ** A hazard ratio less tan 1.0 indicates that the variable leads to an increase of PFS, while a value above 1.0 indicates that it leads to a reduction of PFS Figure 2 . 36-months non-relapse mortality (NRM) and relapse (REL) cumulative incidence estimates from a competing risk model, estimated separately for both conditioning regimens (STANDARD myeloablative and reduced-intensity conditioning=RIC) and two age classes (<=50 years and >50years) Figure 3 . 36-months non-relapse mortality (NRM) and relapse (REL) cumulative incidence estimates from a competing risk model, estimated separately for both conditioning regimens (STANDARD myeloablative and reduced-intensity conditioning=RIC) and three disease status categories at transplant ("untreated", "treated; in CR1" and "treated; not in CR1") 
